JonesTrading Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $40

Moomoo News18:31 ET · Ratings

Intellia Therapeutics Reports Promising Phase 1 Trial Results for Nexiguran Ziclumeran in ATTR Amyloidosis

Quiver QuantitativeNov 16 10:20 ET

Express News | Intellia Announces First Clinical Evidence From Ongoing Phase 1 Study That Nexiguran Ziclumeran (Nex-Z), an in Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (Attr) Amyloidosis

ReutersNov 16 10:16 ET

Intellia Announces First Clinical Evidence From Ongoing Phase 1 Study That Nexiguran Ziclumeran (Nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis

GlobeNewswireNov 16 10:16 ET

Trending Industry Today: Beam Therapeutics Leads Losses In Gene Editing Stocks

Moomoo NewsNov 15 10:30 ET

CCORF Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $90

Moomoo NewsNov 13 08:36 ET · Ratings